Doxorubicin, dacarbazine, vincristine, and cyclophosphamide in the treatment of advanced gastrointestinal leiomyosarcoma.
A multidrug regimen of doxorubicin, dacarbazine, vincristine, and cyclophosphamide produced response in 33% of patients with advanced gastrointestinal leiomyosarcoma. Except for one patient, the duration of response was short and prolongation of survival was not affected.
D000328:Adult; D000368:Aged; D003520:Cyclophosphamide / Q000627:therapeutic use*; D003606:Dacarbazine / Q000627:therapeutic use*; D004317:Doxorubicin / Q000627:therapeutic use*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy*; D006801:Humans; D007890:Leiomyosarcoma / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D014750:Vincristine / Q000627:therapeutic use*
D014750:Vincristine; D003606:Dacarbazine; D004317:Doxorubicin; D003520:Cyclophosphamide